CNN another placement and raise at 0.3c glad i gave up on the stock, despite all the good news it kept getting sold into now we know why
BNE This is from its presentation with the comparisons to other companies or the value benchmarks as it calls it
"Value Benchmarks Transdermal delivery technologies: Acrux Ltd – Australian company (ASX: ACR) – Transdermal delivery technologies, marketed products (Axiron) with Lilly – Market cap: $351m (February 2014) Oral peptide value comparator: Oramed – Israeli company with a US market listing (NASDAQCM: ORMP) – Oral peptide technology, oral insulin in PhIIa clinical trials – Market cap: US$143m (February 2014) Rheumatoid arthritis value comparator: Galapagos – Belgian company (NYSE Euronext: GLPG) – 2012 licencing deal with Abbott for GLPG0634: PhIIa-stage – Selective JAK inhibitor for rheumatoid arthritis – US $150m upfront, $200m at end of PhII, $1b other milestones
